Recent News

• 12.03.2025 - Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
• 11.12.2025 - BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease
• 10.14.2025 - BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
• 10.13.2025 - BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
• 09.18.2025 - BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
• 09.18.2025 - BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
• 09.18.2025 - BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

Recent Filings

• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.12.2025 - DEF 14A Other definitive proxy statements
• 11.12.2025 - EX-99.1 EX-99.1
• 11.12.2025 - ARS Annual Report to Security Holders
• 11.12.2025 - 8-K Current report
• 11.10.2025 - 8-K Current report
• 11.10.2025 - EX-99.1 EX-99.1
• 11.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.31.2025 - PRE 14A Other preliminary proxy statements
• 10.30.2025 - 8-K Current report